Provided by Tiger Trade Technology Pte. Ltd.

Arcutis Biotherapeutics Inc.

25.08
-0.2700-1.07%
Pre-market: 25.140.0600+0.24%09:05 EDT
Volume:2.16M
Turnover:54.13M
Market Cap:3.14B
PE:116.43
High:25.67
Open:25.49
Low:24.73
Close:25.35
52wk High:31.77
52wk Low:15.10
Shares:125.07M
Float Shares:111.18M
Volume Ratio:1.19
T/O Rate:1.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2154
EPS(LYR):-0.1269
ROE:15.86%
ROA:5.09%
PB:14.22
PE(LYR):-197.70

Loading ...

Arcutis management to present at Needham Virtual Healthcare Conference fireside chat

Reuters
·
Apr 01

How New Infant Atopic Dermatitis Data And sNDA Plans At Arcutis (ARQT) Have Changed Its Investment Story

Simply Wall St.
·
Mar 30

Arcutis Biotherapeutics presents new Phase 2 results on Zoryve cream

TIPRANKS
·
Mar 29

Arcutis says Phase 2 trial shows Zoryve cream improves infant atopic dermatitis

Reuters
·
Mar 28

A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price Weakness

Simply Wall St.
·
Mar 19

Arcutis Biotherapeutics to present clinical data on ZORYVE at AAD Meeting

TIPRANKS
·
Mar 18

Arcutis to present new ZORYVE trial data at American Academy of Dermatology annual meeting

Reuters
·
Mar 18

Arcutis Biotherapeutics announces publication on Phase 3 study of Zoryve cream

TIPRANKS
·
Mar 10

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data With Zoryve® (Roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology

THOMSON REUTERS
·
Mar 10

Arcutis Launches First-in-Human ARQ-234 Trial, Expanding Its Atopic Dermatitis Pipeline

TIPRANKS
·
Mar 10

Jefferies Remains a Buy on Arcutis Biotherapeutics (ARQT)

TIPRANKS
·
Mar 09

Press Release: Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth

Dow Jones
·
Mar 05

Arcutis (ARQT) Earnings Call Signals Scaled Growth

TIPRANKS
·
Mar 05

Arcutis Biotherapeutics Director Keith R Leonard Disposes of Common Shares

Reuters
·
Mar 05

Arcutis first participant enrolled in Phase 1a/1b trial of ARQ-234-131

TIPRANKS
·
Mar 03

BRIEF-Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis

Reuters
·
Mar 03

Arcutis Begins Enrolling Phase 1a/1B Study Evaluating Arq-234, a Cd200r Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis

THOMSON REUTERS
·
Mar 03

Arcutis Biotherapeutics Inc. Publishes Transcript of Q4 FY2025 Earnings Call

Reuters
·
Mar 03

Analysts Are Bullish on Top Healthcare Stocks: Arcutis Biotherapeutics (ARQT), Kymera Therapeutics (KYMR)

TIPRANKS
·
Mar 02

MBX Biosciences Says CFO to Step Down; Names Interim Finance Chief

MT Newswires Live
·
Feb 27